RPG Life Sciences Limited on Monday announced its financial results for the third quarter and nine months ending on December 31, 2020. The company engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in profits by 64% yoy and by 16% qoq for Q3FY21, resulting in maintaining the upward trajectory in EBITDA margins, which improved from 15.8% to 19.9% yoy.
The Profit before Tax (PBT) stood at Rs17.07cr up from Rs10.41cr, a growth of 64% yoy. Revenue from Operations at Rs107.60cr registered a growth of 14% yoy and a growth of 11% qoq for Q3FY21.
For 9MFY21 too, EBITDA margins improved from 16.4% to 19.5% yoy. Net revenue for operations stood at Rs296.38cr – up from Rs286.90cr in 9MFY20. PBT from operations stood at Rs44.63cr – up from Rs33.31cr.
“The overall performance of the Company in the third quarter and nine months of this fiscal has been strong despite the magnitude of disruptions caused by the extended Covid‐19 pandemic. Profits grew by 64% and 34% respectively and EBITDA margins retained their upward trajectory yoy for both Q3 and 9 months. Revenue grew by 14% yoy and 11% qoq.
We are focused on executing our turnaround strategy. This comprises of growth initiatives such as product portfolio augmentation, life cycle management of our current brand assets and salesforce effectiveness and profitability improvement measures such as opex control, efficient manufacturing operations and sales hygiene,” Yugal Sikri, Managing Director, RPG Life Sciences Ltd., said.
At around 11.03 am, RPG Life Sciences Ltd was trading at Rs422.80 per piece down by Rs1.85 or 0.44% from its previous closing of Rs424.65 per piece on the BSE.